Clinical and experimental studies show that inhibition of histone/protein deacetylases (HDAC) can have important anti-neoplastic effects through cytotoxic and pro-apoptotic mechanisms. There are also increasing data from non-oncologic settings that HDAC inhibitors (HDACi) can exhibit useful anti-inflammatory effects in vitro and in vivo, unrelated to cytotoxicity or apoptosis. These effects can be cell, tissue or context-dependent, and can involve modulation of specific inflammatory signaling pathways, as well as epigenetic mechanisms.
Introduction
Histone/protein deacetylase inhibitors (HDACi) were initially developed as anti-cancer agents, and much clinical and molecular data regarding their effects arose in the oncology field. However, nowadays HDACi are attracting interest as anti-inflammatory agents, independent of their known pro-apoptotic or cell cycle arrest actions on malignant cells. While pan-HDACi enzymes have the potential to modulate the functions of all cells, their effects on T cells, and on CD4+ FOXP3+ T-regulatory (Treg) cells in particular, are of interest given the burgeoning role for Tregs in the area of cellular therapy. Treg-based therapies, involving ex-vivo expansion and adoptive transfer to boost circulating Treg numbers, are proposed as therapies of neurodegenerative and autoimmune diseases, as well as graft-versus-host disease (GVHD) and organ transplant rejection. 1 However, in inflammatory conditions, conventional T cells can be resistant to suppression by Tregs 2 ,
and pro-inflammatory cytokines (TNF-α, IL-1, IL-6, IFN-γ), LPS and other agents have deleterious effects on Tregs, impairing their suppressive phenotype 3 and promoting their conversion into Th17 4 or Th1 5 cells (as reviewed 6, 7 ). Moreover, the extent to which patients with autoimmune diseases have decreased numbers of Treg cells remains unclear. 8 An alternate therapeutic strategy to transfer of Treg cells is to use pharmacologic agents such as rapamycin 9 or HDACi to curtail T cells responses and facilitate Treg functions. We have shown that
HDACi can enhance Treg suppressive function and promote their development in vitro and in vivo 10 , with beneficial actions for transplantation 11 and autoimmune diseases, including colitis 12, 13 and arthritis. 14 This review summarizes some of the background and promise of HDACi therapy to modulate T cell-associated inflammatory and immunologic diseases. We apologize to those researchers whose work could not be cited due to limited space.
HDAC and HDACi
Histone/protein deacetylases (HDAC) remove acetyl groups (O=C-CH3) from ε -N-acetyl lysine amino acids and are classified into four main classes of enzymes. [15] [16] [17] Class I HDAC include HDAC1, 2, 3, and 8; class II HDAC include HDAC4, 5, 7, 9 (subclass IIa) and HDAC 6, 10 (subclass IIb); class III HDAC are homologs
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Class I HDAC enzymes are expressed in all cells, while class IIa HDAC enzymes have tissue-specific expression. Historically, class I HDAC were thought largely restricted to the nucleus, whereas class IIa HDAC enzymes shuttled between the nucleus and cytoplasm 15, 16 and even mitochondria (HDAC7). 18 However, recent data show that class I HDAC can act in the cytoplasm as well as in the nucleus; e.g. HDAC3 can associate with IκBα in the cytoplasm and translocate into the nucleus in response to TNF-α. 19 Likewise, HDAC1 20 , HDAC2 21 and HDAC8 22 can, on occasion, be identified in cytoplasmic complexes. Class I and IIa HDAC also differ with regard to their catalytic activities. Class I HDAC enzymes exhibit strong deacetylase activity, whereas class IIa HDAC proteins are enzymatically inactive and act primarily as scaffolding or recruiting proteins within large multi-molecular complexes that include class I HDAC (especially HDAC3 23 ) and other regulatory elements. In addition to their well-established role in regulating acetylation of lysines within histone tails and thereby modulating chromatin compaction and remodeling, HDAC enzymes regulate the acetylation of non-histone proteins. More than 1750 non-histone proteins are now identified as HDAC substrates 24 , including p53, GATA1-3, STAT3, STAT5, Foxp3, estrogen and androgen receptors, NF-κB, HSP90 and α -tubulin 25, 26 .
Acetylation of non-histone proteins has varying effects; e.g. increasing (e.g. Foxp3 27 ) or decreasing (e.g. DNMT1 28 ) protein stability, disrupting protein-protein interaction (e.g. NF-κB, HSP70), and increasing transcriptional activation (e.g. p53).
HDACi have differing chemical structures and abilities to inhibit the various HDAC isoforms. 29 The most-studied HDACi, trichostatin-A (TsA) and SAHA, are non-selective, but the development of isoformselective HDACi to target certain processes and avoid unwanted side-effects is an important aim of the ongoing research discussed below. HDACi may inhibit the functions of class IIa enzymes, despite their lack of significant catalytic activity, by binding to their residual catalytic sites and affecting their conformation and/or interactions with other molecules present within multi-molecular complexes. 30 Moreover, HDAC, like many other proteins, are subject to post-translational modifications, including phosphorylation, acetylation, ubiquitylation and sumoylation, and HDACi can modulate the acetylation of HDAC proteins themselves, 35 , and HDACi were shown to alter (mostly inhibit) miRNA levels 36 , providing a novel and, as yet, largely unexplored mechanism for the regulation of class IIa HDAC enzymes.
HDACi and Tregs
Therapy with a pan-HDACi, e.g. TsA or SAHA, can stimulate thymic production of murine Foxp3+ Targeting of Sirt1 also increased Foxp3 expression, but in contrast to our HDAC6 and HDAC9 data, was not associated with increased heat shock responses. Rather, Sirt1 targeting led to upregulation of multiple genes involved in cholesterol metabolism and energy generation through the Krebs cycle and mitochondrial electron transport pathways 48 .
Although many HDAC remain to be evaluated, the available data emphasize the value of targeting particular class II or class III enzymes, whereas our pharmacologic targeting of class I HDAC had no obvious effects on murine Treg function in vitro or in vivo 49 . However, this contrasts with our own 37 and other data 38 using human cells, as well as with data from rat models 50, 51 . Several explanations may apply. Unfortunately, the field lacks a marker to reliably discriminate naturally occurring and induced Tregs, since even Helios, a transcription factor recently proposed of value in this regard 54 , is upregulated upon activation of murine and human conventional T cells 55 . Lastly, HDACi can have important effects on non-Treg cells, especially in vivo, as considered below.
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HDACi and APC
HDACi (pan-, class I-and class IIb-specific) were shown to inhibit the production of multiple proinflammatory cytokines in APC; 56 promote conversion of inflammatory macrophages (M1) into tolerogenic M2 cells 50 ; decrease TLR signaling; 56,57 disrupt antigen presentation 56 , and diminish MHC class II 58 and costimulatory molecule expression. 56 Although the mechanisms of action of HDACi on APC were often uncharacterized in the literature, a key action appears to be HDACi-mediated inhibition of the NF-κB pathway 59 . The net result is to decrease the direct inhibitory signals of inflammation on Tregs, decrease APC stimulation of effector cells, and prevent resistance of Teff cells to Treg-mediated suppression.
Effects of HDACi on development of T cell responses
Key effects of HDACi on the development of host T cell immune responses are illustrated in as soon as 30 minutes of TCR stimulation. This is not dependent on the actions of cytokines or transcription factors, as it occurs under Th1 and Th2 polarizing or non-polarizing conditions, and without T-bet or GATA-3
induction. 60 The rapidity of these events that precede cell division suggests that silencing of lineage-specific cytokine genes in naïve CD4+ cells is regulated by HDAC activity, rather than via the changes at heavily methylated promoters. 61 Indeed, pan-HDACi (TsA) treatment of murine naïve Th0 cells under non-polarizing conditions led to acetylation of histone-4 at the IFN-γ gene locus, and enhanced IFN-γ production to a level comparable with Th1 polarization, in conjunction with inhibition of the Sin3A repressive complex that contains HDAC1 and/or HDAC2. 62 On the other hand, TsA was shown to downregulate CD28 expression in naïve murine CD4+ cells within 4 hours. 63 This effect may be attributable to the toxic effects of high concentrations, given a significant apoptotic rate observed. Our own flow cytometric studies involved use of naive murine cells stimulated with CD3 mAb alone or in the presence of fluorescently labeled pan-HDACi (Pabinostat); Pabinostat was added at a non-toxic concentration (1 nM) that did not affect cell viability, as compared to untreated controls, over the 3 hours of analysis. Consistent with data cited above, HDACi promoted downregulation of a marker of naïve T cells, CD62L, in Teffs (and in naïve Tregs) within 2 hours of exposure ( Fig. 2) , though the underlying mechanisms remain to be determined. Hence, HDACi compounds promote the early activation of CD4+ cells by enhancing histone deacetylation at gene loci responsible for production of Th1 and Th2 lineage cytokines, and also promote cytokine release. Additional experiments are also required to identify the specific HDAC involved in this process.
Stage 2: Division of activated naïve T cells
Shortly after TCR stimulation, naïve T cells begin proliferating, prior to their acquisition of effector functions 64 . Mitosis is largely driven by post-translational modification of histones and proteins, and knockout of both HDAC1 and HDAC2 abrogates cell division at the G1/S phase in primary mouse fibroblasts and in B cells. 65 HDAC1 and HDAC2 are thought to promote cell division by inhibiting p21. 65 HATs also affect the cell cycle; e.g. p300/CBP are essential for the E2F activity that controls the G1/S transition 66 , and TIP60 forms a complex with transformation/transactivation domain-associated protein, providing transcriptional activation of histone genes. 67 Analysis of HeLa cells showed that mitotic cells are notable for their set of highly acetylated proteins, including RNA processing proteins, eIF4G, RNA helicase A, and several cell cycle proteins: APC1, anillin, and NudC. 68 The addition of HDACi compounds typically causes cell cycle arrest and/or mitotic abnormalities, suggesting that class I HDAC enzymes are indispensable for cell division. 68 For themselves (GATA-3, STAT1, STAT6), can be substrates for acetylation 25 and thereby their activity can be regulated by HDAC/HAT balance, but these effects need to be elucidated. Our murine data showed that HDAC6, HDAC9 and Sirt1 KO CD4+ and CD8+ cells displayed normal development, number and phenotypes, comparable to WT T cells. However, conditions of antigen challenge that stimulate Th1/Th2 differentiation can reveal differences; e.g. SLE-prone MRL/lpr HDAC9-/-mice showed decreased cytokine production and inflammation compared to WT mice on the same background 82 . HDACi can also impair the function of transcriptional repressors and thereby disturb lineage commitment regulation. Thus, butyrate can increase acetylation and chromatin remodeling adjacent to the IFN-γ and T-bet gene loci in Th2 differentiating cells 80 .
Likewise, HDACi can inhibit STAT1 83 and STAT6 84 activation, and inhibition of each STAT occurred only when it was upregulated, i.e. STAT6 in Th2-associated dermatitis, and STAT1 in Th1-associated GVHD. 
Alternate route: HDACi, T cell anergy and iTreg differentiation
Early lineage differentiation is especially sensitive to external stimuli, and cells readily become anergic in response to a lack of co-stimulation, altered stability of immunological synapses, and reduced cytokine levels. All of these conditions are enhanced by HDACi use. Indeed, butyrate, TsA, oxamflatin (class I) and scriptaid (class III) were each shown to induce antigen-specific anergy in naïve murine CD4+ T cells by upregulating p21 expression. 70 The significance of p21 upregulation for tolerance induction was shown using two different murine strains; DBA/2 cells had lower p21 expression than C57BL/6 mice, which correlated with impaired tolerance induction by an n-butyrate derivative, MEB. MEB-treated p21-/-cells did not induce tolerance, despite MEB inhibiting cell divisions in all cells to a comparable extent. 85 Hence, induction of tolerance by HDACi does not appear to require inhibition of cell division. Overall, these data suggest that p21 upregulation by HDACi is not responsible for the inhibitory effects of HDACi on T cell division, but is important for development of T cell anergy, at least for murine T cells in vitro. 
Stage 4: Epigenetic lineage memory formation and expansion of effector T cells
Once lineage differentiation is established, a rise in effector cell activity and cytokine release occurs in parallel with expansion, and usually gradually increases during cell divisions 64 . At this stage, increases in the activity of DNMT enzymes lead to DNA methylation and specific and inheritable changes in daughter cells.
Once activated, Th1 and Th2 effector cells become less sensitive to external signals, and permissive histone modifications and increased histone acetylation are observed at sites of lineage-specific genes 60 . Differentiated
Th1 and Th2 cells are less flexible than naïve and early differentiating cells, as illustrated by the inability of retrovirally expressed GATA-3 and dominant-negative T-bet protein to induce normal levels of IL-4 or abrogate IFN-γ expression in Th1 clones 81 . However, Th1 cells retain some flexibility, since human Th1 and Th2 clones can produce both cytokines when cultured under opposing polarizing conditions 81 . This stage is also associated with nuclear export of class IIa HDAC; HDAC7 87 was shown as regulator of cytokine production in T cells, and restricting HDAC localization to the nucleus inhibited cytokine production. HDACi use can affect Teff cell development and function at this stage. Thus, TsA and class I-specific FR901228 inhibited initial and ongoing proliferation of human CD4+ cells, and caused CD154 downregulation in freshly stimulated, pre-activated and in 21-days expanded CD4+ cells 78 . Also, in vivo models in which HDACi treatment was started after 
Stage 5: Memory T cell differentiation
As inflammation resolves and cytokine levels decrease, activated effector cells die or become resting memory cells. Memory cells do not produce cytokines, but are able to reactivate lineage-specific effector genes during the first hours after the antigen challenge, providing a fast and robust adaptive immune response. 60, 87 Memory cell formation involves epigenetic mechanisms, including methylation and acetylation. IL-2-promoter and IFN-γ enhancer are demethylated in CD8+ memory cells 88 , and have the permissive acetylated histone marks, H3K9Ac, characteristic of active genes. Similarly, CD4+ memory cells have increased acetylation at appropriate cytokine loci 89 . Interestingly, when memory CD8+ memory formation was disrupted by an absence of the CD4+ help that is required for this process, the IFN-γ locus lost acetylation, and HDACi treatment restored acetylation and function of CD8+ memory cells 88 . 
Safety and side-effects of HDACi and future directions
Most of the current clinical data involves use of pan-HDACi or class I HDACi at relatively high concentrations in oncology settings. Side effects include neutropenia or leukopenia, thrombocytopenia, intestinal problems (anorexia, nausea, vomiting, diarrhea), electrolyte disturbances and profound fatigue 99 .
Except for neurocortical disturbances such as confusion and tremor, which were reported mainly with butyrate and valproate, no marked differences in adverse effects or in anticancer activity were seen between pan-HDACi and class I HDACi. Overall, HDACi were better tolerated and had less toxicity than conventional chemotherapeutic agents, but in non-life-threatening conditions, even somewhat reduced levels of side effects may be unacceptable. It is anticipated that the HDACi concentrations capable of providing anti-inflammatory responses will be lower and involve less toxicity than the levels used in oncology trials, and the first clinical 
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